RAPID C-19 Oversight Group report: review of Evusheld
A summary of the evidence on efficacy of Evusheld as a prophylactic treatment for coronavirus (COVID-19) considered by the RAPID C-19 Oversight Group.
Documents
Details
In February 2021, the Chief Medical Officer commissioned the to review the efficacy of Evusheld (tixagevimab plus cilgavimab) as a pre-exposure prophylaxis used in the treatment of coronavirus (COVID-19). This report summarises the group鈥檚 recommendations.
Pre-exposure prophylaxis is when therapeutic drugs are taken before exposure to COVID-19 to help build up protection against the virus.
The RAPID C-19 Oversight Group concluded that the quality of existing data is insufficient to warrant emergency procurement of the drug prior to .
This report has been published alongside a letter from the Secretary of State for Health and Social Care to a group of charities and patient groups, which provides more information on the decision not to procure Evusheld and what the government鈥檚 next steps will be.